

# 2013 results

24th July 2013





# Introduction



# I am pleased to report the Group's results for the year ended 30th June 2013, with record annual revenue in this, the Group's 40th anniversary year


## Chairman's statement highlights

- Record revenue of £346.9m (2012 £331.9m)
- Continued investment in R&D and new product launches
- Further expansion of our marketing infrastructure
- Integration of acquired businesses
- Adjusted profit before tax £81.5m (2012 £86.0m)
- Capital expenditure investment of £28.0m
- Strong balance sheet with £26.6m cash (2012 £21.1m)
- Receipt of 16th Queen's Award
- Appointment of 2 new non-executive directors
- New investor communication policy
- Dividend for the year of 40.0p (2012 38.5p), 4% increase


# **Financial highlights**

	2013 £m	2012 £m	Change %
Revenue	346.9	331.9	+5%
Adjusted operating profit	79.1	83.2	-5%
Adjusted profit before tax	81.5	86.0	-5%
	Pence	Pence	
Adjusted earnings per share	91.4	95.6	-4%
Dividend per share	40.0	38.5	+4%

Adjusted figures are in respect of the year ended 30th June 2013 and exclude a £2.9m gain on an early settlement of deferred consideration relating to the purchase of the remaining 34% shareholding in Measurement Devices Limited (MDL).




Adjusted profit before tax £m



#### Income statement

	2013	<b>A</b> (	2012	<i></i>	
	£m	%	£m	%	Change
Revenue	346.9	100	331.9	100	+5%
Cost of sales	116.0	33	110.0	33	+5%
Engineering (inc. R&D)	48.7	14	45.0	14	+8%
Gross profit	182.2	53	176.9	53	+3%
Distribution costs	69.4	20	62.2	19	+12%
Administrative costs	33.7	10	31.5	9	+7%
Adjusted operating profit	79.1	23	83.2	25	-5%
Financial income (net)	1.4	-	2.1	1	-
Profit from associates	1.0	-	0.7	-	
Adjusted profit before tax	81.5	23	86.0	26	-5%



# Income statement – Adjusted operating profit

Adjusted operating profit - segmental			
	2013 £m	2012 £m	Change %
Metrology	84.5	91.8	-8%
Healthcare	(5.4)	(8.6)	-37%
Total adjusted operating profit	79.1	83.2	-5%




# Income statement – Quarterly results

Revenue - quarterly			
	2013 £m	2012 £m	Change %
Quarter 1	95.9	70.5	+36%
Quarter 2	78.3	76.7	+30%
Quarter 3	81.9	81.6	+2 %
Quarter 4	90.8	103.1	-12%
Total	346.9	331.9	+5%

#### **Profit before tax - quarterly**


	2013 £m	2012 £m	Change %
Quarter 1	28.3	13.6	+108%
Quarter 2	15.0	17.5	-14%
Quarter 3	16.5	21.4	-23%
Quarter 4	21.7	33.5	-35%
Total	81.5	86.0	-5%





# Income statement – Engineering costs

Engineering costs			
	2013 £m	2012 £m	Change %
Total spend	51.8	47.9	+8%
Less capitalised	3.1	2.9	+7%
Income statement	48.7	45.0	+8%
Total spend segmental	2013 £m	2012 £m	Change %
Metrology	40.2	34.6	+16%
Healthcare	8.5	10.4	-18%



#### Income statement – Distribution costs

#### **Distribution costs**

•Expansion of global marketing and distribution infrastructure to support new and existing products

•Group becoming increasingly involved in the provision of systems solutions

•Recruitment of 94 sales, marketing and applications engineering staff

•Eleventh office opened in China, with a new liaison office in Wuhan

#### Distribution costs £m



# Income statement – Administrative costs and Group headcount

Group headcount (at June)			
	2013 No.	2012 No.	Change No.
UK & Ireland	2,261	1,996	+265
Overseas	974	908	+66
Total	3,235	2,904	+331


•Continued growth in headcount to support higher production, increased investment in new product development and expansion of marketing and support facilities

- •Headcount up 331 from June 2012
- •Increase in staff includes 20 apprentices and 32 graduates

•Additionally we are sponsoring 36 students at UK universities mostly on engineering, science and software courses




Group headcount (year end) No.






#### Income statement – variances from previous year





## Adjusted earnings per share and Dividend per share




#### Group revenue analysis

Changes in geographic area			
	Change %		
Far East	+7%		
Europe	+0%		
Americas	+3%		
UK & Ireland	+9%		
Total	+5%		

#### **Revenue by major countries**

	2013 £m	2012 £m
China	75.2	65.2
USA	66.4	64.6
Germany	41.1	42.5
Japan	35.7	38.5




#### Group revenue analysis

Revenue			
	2013 £m	2012 £m	Change %
Metrology	317.9	305.8	+4%
Healthcare	29.0	26.1	+11%
Total	346.9	331.9	+5%


•Record revenue, up 5% at actual exchange rates

•No significant difference in revenue value when re-stated at previous year's exchange rates



# Group revenue analysis - Metrology

Revenue			
	2013 £m	2012 £m	Change %
Metrology	317.9	305.8	+4%
Changes in geograp	ohic area		0
			Change %
Far East			+5%
Europe			+1%
Americas			+4%
UK & Ireland			+6%
Results			
		2013	2012
		£m	£m
Operating profit		84.5	91.8



# Metrology highlights

•Good growth in machine tool probing products, particularly relating to the consumer electronics market in the Far East

•Encoder product line now showing growth, following recovery in electronics and semiconductor industries

•Good growth in the measurement automation product line, with more widespread acceptance

Increased R&D investment

•Exhibition of the Group's additive manufacturing products, the Equator gauging system and calibration products, XR20-W rotary axis calibrator system and XL-80 laser measurement system, at Euromold 2012 in November

•Purchase of business assets of LBC LaserBearbeitungsCenter GmbH, in Germany, a pioneer in the field of additive manufacturing for tool and mould making



#### PH10 PLUS probe head



Next generation of PH10 with improved service and diagnostics capability


#### PHC10-3/PI 200-3

#### TCR20




New module change rack for 5-axis touch trigger inspection systems

#### MODUS Point Cloud sectioning



Software for on-surface sectioning through a cloud of tip centre data points, previously captured by REVO

#### UCCsuite 4.5




An integrated head and probe

interface for CMM OEMs


Latest release with increased UCC security, enhanced PH20 metrology and improvements to rack alignment

#### Surfitblade




Software for reverse engineering of airfoils

#### APEXBlade v1.3



New functionality added to path planning and automatic program creation software for airfoil blades

#### Productivity+™ v 1.90



Full support for multi-axis machine tool configurations

#### RTS



For cableless radio tool setting and broken tool detection on CNC machining centres

# Equator process monitor software



Giving operators an instant status monitor, history of gauging and ability to manage re-mastering

#### RMI-Q



Radio machine interface for operation of multiple Renishaw radio transmission probes

#### Equator<sup>™</sup> 300 Extended Height



Gives users an extra 150mm Z-height below the standard measuring volume to accommodate large fixtures and automation systems


#### Equator EZ-IO automation

software



Allowing easy setup of communications in automated cells

**RVC Siemens software** 



Volumetric compensation software for Siemens controllers

HS20 long range laser encoder HC20 compensation system



With a range of up to 60m, for use on large machine tools (commonly found in aerospace and marine industries)

#### Off-axis rotary software



For the XR20-W rotary calibrator



Upgrade for HC10

#### RESOLUTE™ UHV



Ultra-high vacuum compatible readhead

# Wrap-up incremental rotary encoder for large diameters



Spring supported magnetised scale with built in tensioning mechanism

#### **RESOLUTE DRIVE-CLIQ**



RESOLUTE true-absolute linear and rotary encoders with new compatability for Siemens DRIVE-CLiQ interface

# AksIM<sup>™</sup> off-axis absolute rotary encoder



A range of robust off-axis absolute rotary encoders designed for limited space applications.


#### GEO space angle encoder



Space-qualified encoder with high radiation hardness and very high accuracy (developed in collaboration with TESAT)

# Group revenue analysis - Healthcare

Revenue			
	2013 £m	2012 £m	Change %
Healthcare	29.0	26.1	+11%
Changes in geographic	area		
			Change %
Far East			+28%
Europe			-3%
Americas			-15%
UK & Ireland			+44%
Results			
		2013 £m	2012 £m
Operating (loss)		(5.4)	(8.6)



# Healthcare highlights

•Good growth in spectroscopy product line

•Sales of a number of stereotactic robots during the year, to Europe and the Middle East

•Growing medical and clinical interest in devices for delivering therapies into the brain

•Growing demand for dental frameworks for crowns and bridges


•Increasing use of our additive manufacturing products in dental manufacturing processes

•Reduced loss for the year with the objective of at least breaking even over the next two years



# New product releases / Healthcare

WiRE4 software for inVia system



Enabling users to collect and work with larger Raman data files, seeing greater detail and richer images

Eclipse filters for inVia system


Making imaging of low wave number Raman bands, which contain important chemical and structural information, easy

#### Neuroinspire<sup>™</sup> V 2.1 and V 3.0



Including support for SEEG procedures used in the treatment of Epilepsy.

#### Renishaw dental studio



Gives dental technicians the freedom to design bespoke dental restorations to the exact shape they require.

# Awards

•In April 2013, Renishaw received a Queen's Award for Enterprise 2013 in the Innovation category for its revolutionary REVO® five-axis multi-sensor probing system. The REVO is used on co-ordinate measuring machines (CMMs) to significantly improve accuracy and throughput when inspecting complex parts including aero-engine blades, automotive cylinder blocks and many types of gears. This is the Company's sixteenth Queen's Award since its formation in 1973, and its seventh in just ten years.

•Renishaw's assembly facility at Woodchester in Gloucestershire was named as the UK's Best Electronics & Electrical Plant at the prestigious Best Factory Awards 2012 held on 28<sup>th</sup> September 2012 in London. The honour was achieved against strong competition from global brands.







## Board of directors – Non-executive changes

•Retirement of David Snowden and Terry Garthwaite having each completed nine years on the Board.

•On 19th October 2012, Carol Chesney, a chartered accountant and company secretary at the manufacturing group Halma plc, joined the Board as a non-executive director and chair of the Audit committee.

•Dr David Grant has been appointed the chair of the Remuneration committee in place of David Snowden.

•On 11th April 2013, John Jeans joined the Board as a non-executive director. He is Chair of the Council of Cardiff University and of Imanova (a research partnership). He also chairs the Board of MRC Technology and is a non-executive director of the Alliance Medical Group.








# Cash flow

#### Change in cash balance for the period £m



#### Balance sheet

£m	June 2013	June 2012	Change %
Property, plant & equipment	117.9	101.0	+17%
Intangible assets & investments	63.5	61.2	+4%
Deferred tax assets	18.3	17.8	+3%
Derivatives	8.0	3.5	+129%
Total non-current assets	207.7	183.5	+13%
Inventory	65.3	54.0	+21%
Debtors	83.7	100.0	-16%
Pension fund cash escrow	11.0	11.5	-4%
Cash	26.6	21.1	+26%
Creditors (current)	(43.9)	(56.4)	-22%
Net current assets	142.7	130.2	+10%
Deferred tax liability	(20.0)	(19.5)	+3%
Pension fund deficit	(41.7)	(42.0)	-1%
Other payables	(12.0)	(9.8)	+22%
Net assets, equal to Total equity	276.7	242.4	+14%



#### Working capital (excluding Cash) £m



2013 results

# Capital expenditure

	2013 £m	2012 £m
Capital expenditure	28.0	30.3

•Property

•Completion of building for MDL product line of 20,000 sq ft in York

•Further refurbishment of Miskin, South Wales – additional 66,000 sq ft


•Expansion of Ireland manufacturing facility of 26,000 sq ft

•Start of 120,000 sq ft new build at New Mills

•Purchase of property in Canada for MDL subsidiary


•Plant & equipment

•Machinery for extended Miskin facility, including new anodising plant and electronic production equipment





# Capital expenditure - property





Second stage Miskin refurbishment






# Capital expenditure - property



New building in York, occupied by MDL product line





Canada property for MDL subsidiary





# Capital expenditure - property



New Mills development in progress



Architect's design

# Miskin plans



existing buildings

Renishaw is preparing a planning application for two million sq ft of development in South Wales. The proposal has the potential to create hundreds of jobs, generated by Renishaw's own expansion and the new businesses that would be attracted to the 77 hectare site.

The site in Miskin, near Cardiff, was allocated as a strategic employment site by the Vale of Glamorgan Council in 2012. Renishaw intends to occupy 19 hectares of the site and 58 hectares may be put out for sale to fund the further expansion of activities on Renishaw's retained land.

The plan outlines proposals which include a 1 million sq ft warehouse and a new business park. The space could include manufacturing, research and development, office and distribution and will target engineering and logistics firms and their supply chains.



Renishaw completed the purchase of the 461,000 sq ft facility and surrounding land in September 2011 and has recently refurbished 68,500 sq ft of space in which it commenced manufacturing in May 2012. A further 66,000 sq ft has recently been refurbished. The company has future plans to build an additional 400,000 sq ft of manufacturing, research and development facilities for its further expansion.

#### Investor communication

During the year the Board has reviewed its policy on communications with shareholders and the analyst and investor community. The Board will provide all shareholders with information at the same time, in the same forum or medium, and ensure that the level and quality of information provided is significantly enhanced.

As a consequence, no private meetings will be held by directors with investors, potential investors or analysts, however, shareholder meetings with the Chairman, the Senior independent director and/or any other non-executive director may be arranged where a shareholder wishes to communicate their views.

The corporate website is being significantly expanded. The Group's year end and half year results will continue to be delivered by way of webcasts with time allowed for questions and answers. In addition to the AGM, normally held in October, at which company presentations and tours are arranged, a corporate shareholder and investor day will be held annually in May.




# Outlook

During the year the Group has further consolidated its leading position in its principal markets, as well as investing for future growth and expansion. There is an extensive new product pipeline and strategy for each of our business segments and a number of new product introductions are anticipated in this current financial year.

The Group faces tough comparators going into the first half of this financial year, however, we look forward with confidence to a successful 2014.






# Cash flow from operating activities

	2013 £m	2012 £n
Adjusted profit before tax	81.5	86.0
		00.
Depreciation and amortisation	21.1	20.
Financial income and expenses	(1.4)	(2.2
Share of profits from associates	(1.3)	(1.0
Increase in inventory	(11.3)	(4.0
Decrease/(increase) in debtors	15.3	(24.7
(Decrease)/increase in creditors	(6.1)	8.4
Total movement in working capital	(2.1)	(20.3
DB pension contributions	(2.5)	(1.4
Income taxes paid	(15.7)	(14.1
Cash from operating activities	79.6	67.



# Cash flow

	2013 £m	201 £r
Cash from operating activities	79.6	67.
Interest received less paid	0.8	0.
Dividends paid less received	(28.5)	(25.4
Fixed assets purchased (net)	(27.7)	(29.
Intangible assets acquired	(1.2)	(3.
Deferred consideration payments	(7.5)	(2.
Development costs capitalised	(10.6)	(9.
Net movement in escrow account	0.5	(0.
Net cash flow	5.4	(4.
Cash at 1st July	21.1	23
Effect of exchange rate changes	0.1	2
Cash at 30th June	26.6	21



## Disclaimer

This document contains statements about Renishaw plc that are or may be forward-looking statements.

These forward-looking statements are not guarantees of future performance. They have not been reviewed by the auditors of Renishaw plc. They involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of any such person to be materially different from any results, performance or achievements expressed or implied by such statements. They are based on numerous assumptions regarding the present and future business strategies of such persons and the environment in which each will operate in the future. All subsequent oral or written forward-looking statements attributable to Renishaw plc or any of its shareholders or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included in this document speak only as of the date they were made and are based on information then available to Renishaw plc. Investors should not place undue reliance on such forward-looking statements, and Renishaw plc does not undertake any obligation to update publicly or revise any forward-looking statements.

No representation or warranty, express or implied, is given regarding the accuracy of the information or opinions contained in this document and no liability is accepted by Renishaw plc or any of its directors, members, officers, employees, agents or advisers for any such information or opinions.

This information is being supplied to you for information purposes only and not for any other purpose. This document and the information contained in it does not constitute or form any part of an offer of, or invitation or inducement to apply for, securities.

The distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of laws of any such other jurisdiction.